SLM's 15-minute chart shows MACD Death Cross and KDJ Death Cross.

According to SLM's 15-minute chart, a MACD Death Cross and KDJ Death Cross occurred on August 19, 2025 at 10:00. This suggests that the stock price has a high likelihood of continuing its downward trend, with the momentum shifting towards the downside and potentially leading to further decreases in the stock price.

Ainos, Inc. (NASDAQ:AIMD) has reported significant progress in the commercialization of its AI Nose platform during the second quarter ended June 30, 2025. The company announced a strategic inflection point, transitioning from research and development to revenue-generating deployment, particularly in Japan's senior care sector and the semiconductor industry.

Chun-Hsien (Eddy) Tsai, Chairman, President, and CEO of Ainos, highlighted the platform's growing commercial momentum. "The first half of 2025 marked a strategic inflection point as we successfully transitioned from R&D to revenue-generating deployment in Japan," Tsai said. "With new real-world pilot programs underway and a clear path to scaled adoption, we've set the stage for the second half with accelerating momentum and expanding commercial traction."

A key milestone was the announcement of a three-year subscription order valued at $2.1 million with ASE Technology Holding Co., Ltd. (ASEH), the world's largest provider of semiconductor assembly and test services. This represents the first commercial success of Ainos' AI Nose platform in the semiconductor manufacturing sector.

The company also reported impressive performance metrics, with AI Nose achieving 85% accuracy in eldercare hygiene detection, 80% at Japanese semiconductor facilities, and 90% in classifying food and beverage scents. These results validate the robustness and versatility of the company's scent language models (SLMs).

Ainos has a well-defined roadmap for the second half of 2025, including the completion of approximately 1,400 pilot deployments of AI Nose with ASEH and the launch of Phase 1 expansion to around 5,000 units. The company is also planning to showcase the AI Nose-integrated robot with its partners at Automation Taipei in late August.

Financial highlights include significant first-half revenue growth through the co-development project in Japan's senior care sector and improved gross margin, turning to gross profitability in both Q2 and the first half. Operating cash outflows narrowed by 26% year over year, while the company continued to invest in R&D, AI Nose validation, and clinical trials.

Ainos has also announced a 90-day action plan to advance its SmellTech platform and unlock the next wave of AI-powered sensing. This plan aligns with other 2H25 priorities and positions the company for scale-up in 2026.

Overall, Ainos' strong momentum in AI Nose commercialization and strategic partnerships suggest a promising outlook for the second half of 2025 and beyond.

References:
[1] https://finance.yahoo.com/news/ainos-reports-second-quarter-2025-201500361.html